A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- RANDOMIZED · SEQUENTIAL · TREATMENT · SINGLE
- Evidence population
- Human clinical study registration
- Participants
- 66
- Population
- ALL · 65 Years
- Duration
- 2024-06-03 to 2027-12-01
- Intervention
- umbilical cord mesenchymal stem cells
- Comparator
- Phase II Placebo Arm
- Outcomes measured
- Incidence of Treatment-Emergent Adverse Events (TEAEs)/ Serious Adverse Events (SAEs). — Up to 12 months through study; Incidence of withdrawals due to adverse events — Up to 12 months through study; vital signs — Up to 12 months through study; physical examination — Up to 12 months through study; clinical laboratory test results — Up to 12 months through study; electrocardiogram — Up to 12 months through study; Mean change from baseline in frailty status (Cardiovascular Health Study [CHS] frailty score — change from baseline to…; Mean change from baseline in grip strength — change from baseline to Day 91, Day 181, and Day 361; Mean change from baseline in chair-stand test — change from baseline to Day 91, Day 181, and Day 361; Mean change from baseline in muscle mass and bone density — change from baseline to Day 91, Day 181, and Day 361; Mean change from baseline in quality of life measured by change in SF-12 — change from baseline to Day 91, Day 181, and…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Stem cells · 100%Title contains controlled term: stem cell. Abstract contains controlled term: stem cell. Source terminology contains: stem cell. Title supplies longevity context: frailty, frail. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.